Loading...

    Explore
    • Policy Monitoring
    • Live Policy Feed
    • Billing Codes
    • Healthcare Providers
    • Health Insurance Payers
    • States
    • Service Lines
    • Taxonomy Codes
    Lookup tools
    • Billing Code Lookup
    • CPT Modifier Lookup
    • Provider Taxonomy Code Lookup
    • Healthcare Provider & Facility Lookup
    • Health Insurance Payer Lookup
    • Payer Contact Directory

    Policy & Benchmark Tools

    • Prior Authorization Lookup
    • Coverage Criteria Lookup
    • Timely Filing Lookup
    • Billing Code Reimbursement Rates
    • Payer Comparison Dashboard
    • Facility Comparison Dashboard
    • All tools

    Company

    • About OpenPayer
    • Data Sources
    • Trek Health
    OpenPayerby Trek Health
    LinkedInYouTube

    © 2026 Trek Health. All rights reserved.

    OpenPayer is built and maintained by Trek Health.

    v1.0.31
    OpenPayerPolicy UpdatesPharmacy & Specialty DrugsBCBS South Dakota Ultomiris Prior Auth | OpenPayer
    Ask Trek AI about this page
    CurrentBlue Cross Blue Shield - South DakotaPolicy 05.02.86

    Ultomiris (ravulizumab) Coverage Criteria

    Customize your policy alerts

    Sign up for blue cross blue shield - south dakota Policy 05.02.86 alerts

    Get alerted when Policy 05.02.86 changes without checking for updates manually.

    Monitor payer policy activity

    Receive email alerts as soon as relevant payer policies are published or updated.

    This policy governs prior authorization and medical-necessity coverage for Ultomiris (ravulizumab) used to treat paroxysmal nocturnal hemoglobinuria, atypical hemolytic uremic syndrome, generalized myasthenia gravis, and neuromyelitis optica spectrum disorder. Coverage requires applicable diagnosis-specific criteria, documentation, and absence of therapy exclusions.

    Policy Summary
    PayerBlue Cross Blue Shield - South Dakota
    PolicyUltomiris (ravulizumab) Coverage Criteria
    Policy CodePolicy 05.02.86
    Change TypeNo material change
    Effective DateMay 30, 2025
    Last ReviewOct 1, 2026
    Next Review DateN/A
    Key ActionSubmit prior authorization with diagnosis-specific clinical and laboratory documentation for new treatment requests, or positive-response documentation for reauthorization.
    SourceLink
    POLICY UPDATE CHANGES

    No material clinical or coverage changes in this revision.

    4FDA-approved indications addressed

    OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.

    6 monthsInitial authorization period
    12 monthsContinuation authorization period
    ≥6Required MG-ADL score
    J1303HCPCS code for ravulizumab

    Coverage Criteria

    Initial Therapy — PNH

    Authorization of 6 months may be granted for treatment of paroxysmal nocturnal hemoglobinuria (PNH) when all of the following criteria are met:

    ALL of the following

    • ONE of the following diagnostic thresholds

      • PNH cells comprise at least 5% of cells>= 5% PNH cells
      • At least 51% of granulocytes are glycosylphosphatidylinositol-anchored protein (GPI-AP) deficient>= 51% GPI-AP deficient polymorphonuclear cells
    • The diagnosis of PNH was confirmed by detecting a deficiency of glycosylphosphatidylinositol-anchored proteins (GPI-APs) using flow cytometry.
    • For subcutaneous dosing, the member is 18 years of age or older.>= 18 years

    Initial Therapy — aHUS

    Authorization of 6 months may be granted for treatment of atypical hemolytic uremic syndrome (aHUS) not caused by Shiga toxin when all of the following criteria are met:

    ALL of the following

    • ADAMTS13 activity level is above 5%.> 5%
    • Shiga toxin is absent.
    • For subcutaneous dosing, the member is 18 years of age or older.>= 18 years

    Initial Therapy — gMG

    Authorization of 6 months may be granted for treatment of generalized myasthenia gravis (gMG) when all of the following criteria are met:

    ALL of the following

    • The member is anti-acetylcholine receptor (AChR) antibody positive.
    • Myasthenia Gravis Foundation of America (MGFA) clinical classification is II to IV.MGFA II–IV
    • MG activities of daily living (MG-ADL) total score is at least 6.MG-ADL >= 6
    • ONE of the following treatment-history criteria

      • The member has failed treatment over at least one year with at least two immunosuppressive therapies, such as azathioprine, cyclosporine, mycophenolate, tacrolimus, methotrexate, cyclophosphamide, or rituximab.

    Initial Therapy — NMOSD

    Authorization of 6 months may be granted for treatment of neuromyelitis optica spectrum disorder (NMOSD) in adults when all of the following criteria are met:

    ALL of the following

    • The member is anti-aquaporin-4 (AQP4) antibody positive.
    • The medication is prescribed by, or in consultation with, a neurologist.
    • ONE of the following core clinical characteristics

      • Optic neuritis.
      • Acute myelitis.
      • Area postrema syndrome, consisting of an episode of otherwise unexplained hiccups or nausea and vomiting.

    Continuation Therapy — PNH

    Authorization of 12 months may be granted for continued treatment in members requesting reauthorization when all of the following criteria are met:

    ALL of the following

    • There is no evidence of unacceptable toxicity or disease progression while on the current regimen.
    • The member demonstrates a positive response to therapy, such as improvement in hemoglobin levels or normalization of lactate dehydrogenase (LDH) levels.

    Continuation Therapy — aHUS

    Authorization of 12 months may be granted for continued treatment in members requesting reauthorization when all of the following criteria are met:

    ALL of the following

    • There is no evidence of unacceptable toxicity or disease progression while on the current regimen.
    • The member demonstrates a positive response to therapy, such as normalization of lactate dehydrogenase (LDH) levels or platelet counts.

    Continuation Therapy — gMG

    Authorization of 12 months may be granted for continued treatment in members requesting reauthorization when all of the following criteria are met:

    ALL of the following

    • There is no evidence of unacceptable toxicity or disease progression while on the current regimen.
    • The member demonstrates a positive response to therapy, such as improvement in MG-ADL score or a change from baseline in Quantitative Myasthenia Gravis (QMG) total score.

    Continuation Therapy — NMOSD

    Authorization of 12 months may be granted for continued treatment of NMOSD in anti-AQP4 antibody-positive adults requesting reauthorization when all of the following criteria are met:

    ALL of the following

    • There is no evidence of unacceptable toxicity or disease progression while on the current regimen.
    • The member demonstrates a positive clinical response to therapy from baseline, as shown by a reduction in the number and/or severity of relapses.
    • The medication is prescribed by, or in consultation with, a neurologist.

    Ultomiris is not indicated for the treatment of patients with Shiga toxin Escherichia coli-related hemolytic uremic syndrome (STEC-HUS).

    For gMG, Ultomiris must not be used in combination with another complement inhibitor, such as Soliris or Zilbrysq, or a neonatal Fc receptor blocker, such as Vyvgart, Vyvgart Hytrulo, or Rystiggo.

    For NMOSD, Ultomiris must not be administered concomitantly with other complement inhibitors, such as eculizumab; anti-CD20 therapy, such as rituximab; an anti-CD19 antibody, such as inebilizumab-cdon; or an interleukin-6 (IL-6) receptor antagonist, such as satralizumab-mwge.

    Ultomiris is considered not medically necessary for members who do not meet the criteria set forth above.

    Coding and Clinical Thresholds

    HCPCS Billing CodeHCPCS
    J1303Injection, ravulizumab-cwvz, (Ultomiris), 10 mg
    Procedures and Billing CodesHCPCS
    J1303Injection, ravulizumab-cwvz, (Ultomiris), 10 mg
    PNH cells
    PNH diagnosis confirmationAt least 5% PNH cells
    Required testingFlow cytometry must demonstrate GPI-AP deficiency
    Subcutaneous dosingMember must be 18 years of age or older
    GPI-AP-deficient polymorphonuclear cells
    PNH diagnosis confirmationAt least 51% of GPI-AP-deficient polymorphonuclear cells
    Required testingFlow cytometry must demonstrate GPI-AP deficiency
    Subcutaneous dosing

    Provider Actions and Submission Requirements

    Prior Authorization

    Prior Authorization Required

    Prior authorization is required for Ultomiris treatment. Submit the applicable clinical documentation for initial requests and reauthorization requests; initial authorizations are generally granted for 6 months, while continued NMOSD treatment may be authorized for 12 months when continuation criteria are met.

    • Initial requests must meet the diagnosis-specific criteria for PNH, aHUS, gMG, or NMOSD.
    • Reauthorization requests must include documentation of ongoing eligibility and positive clinical response; the NMOSD continuation authorization period is 12 months.
    Documentation Required

    Initial Clinical Documentation

    Include diagnosis-specific clinical documentation with every initial prior authorization request to support the requested indication.

    • aHUS: ADAMTS13 activity level.

    Therapy Background

    Ultomiris (ravulizumab) is a terminal complement-inhibiting therapy. This policy addresses coverage for paroxysmal nocturnal hemoglobinuria (PNH), atypical hemolytic uremic syndrome (aHUS), anti-acetylcholine receptor (AChR) antibody-positive generalized myasthenia gravis (gMG), and anti-aquaporin-4 (AQP4) antibody-positive neuromyelitis optica spectrum disorder (NMOSD). Coverage is subject to the applicable diagnosis-specific clinical criteria, documentation requirements, and therapy restrictions.

    Clinical Definitions

    NMOSD core clinical characteristics
    Optic or spinal manifestationsOptic neuritis or acute myelitis
    Area postrema manifestationArea postrema syndrome, including otherwise unexplained hiccups or nausea and vomiting
    Brainstem manifestationAcute brainstem syndrome
    Diencephalic manifestationSymptomatic narcolepsy or acute diencephalic clinical syndrome with NMOSD-typical diencephalic MRI lesions
    Cerebral manifestationSymptomatic cerebral syndrome with NMOSD-typical brain lesions

    Initial Therapy Criteria

    PNH — 6-Month Initial Authorization

    Authorization of 6 months may be granted when all criteria are met.

    6-month initial PNH authorization

    • PNH laboratory confirmation

      • At least 5% PNH cells.≥5% PNH cells
      • At least 51% of GPI-AP-deficient polymorphonuclear cells.≥51%
    • Flow cytometry is used to demonstrate GPI-AP deficiency.

    Continuation Therapy Criteria

    PNH — 12-Month Continuation Authorization

    Authorization of 12 months may be granted for continued treatment when all criteria are met.

    12-month continuation PNH authorization

    • There is no evidence of unacceptable toxicity or disease progression while on the current regimen.
    • The member demonstrates a positive response to therapy, such as improvement in hemoglobin levels or normalization of LDH levels.

    aHUS — 12-Month Continuation Authorization

    Authorization of 12 months may be granted for continued treatment when all criteria are met.

    12-month continuation aHUS authorization

    • There is no evidence of unacceptable toxicity or disease progression while on the current regimen.
    Policy Summary
    PayerBlue Cross Blue Shield - South Dakota
    PolicyUltomiris (ravulizumab) Coverage Criteria
    Policy CodePolicy 05.02.86
    Change TypeNo material change
    Effective DateMay 30, 2025
    Last ReviewOct 1, 2026
    Next Review DateN/A
    Key ActionSubmit prior authorization with diagnosis-specific clinical and laboratory documentation for new treatment requests, or positive-response documentation for reauthorization.
    SourceLink
    On This Page
    Coverage CriteriaCoding and Clinical ThresholdsProvider Actions and Submission RequirementsTherapy BackgroundClinical DefinitionsInitial Therapy CriteriaContinuation Therapy Criteria
    >= 1 year and >= 2 immunosuppressive therapies
  1. The member has failed at least one immunosuppressive therapy and required chronic plasmapheresis or plasma exchange (PE) or intravenous immunoglobulin (IVIG).
  2. Acute brainstem syndrome.
  3. Symptomatic narcolepsy or acute diencephalic clinical syndrome with NMOSD-typical diencephalic MRI lesions.
  4. Symptomatic cerebral syndrome with NMOSD-typical brain lesions.
  5. The member has experienced a relapse that required rescue therapy in the 12 months before initiating therapy.Relapse requiring rescue therapy within the last 12 months
  6. Member must be 18 years of age or older
    ADAMTS13 activity
    ADAMTS13 activityAbove 5%
    Shiga toxinShiga toxin must be absent
    Subcutaneous dosingMember must be 18 years of age or older
    MGFA clinical classification
    Qualifying MGFA classificationClass II to IV
    AChR antibody statusAnti-acetylcholine receptor antibody positive
    MG-ADL scoreTotal score ≥6
    MG-ADL total score
    Qualifying MG-ADL scoreTotal score ≥6
    AChR antibody statusAnti-acetylcholine receptor antibody positive
    MGFA classificationClass II to IV
    NMOSD relapse history
    Required relapse historyA relapse requiring rescue therapy within the 12 months before therapy initiation
    Antibody statusAnti-aquaporin-4 (AQP4) antibody positive
    Specialist involvementMedication prescribed by, or in consultation with, a neurologist
  7. PNH: Flow cytometry demonstrating deficiency of glycosylphosphatidylinositol-anchored proteins (GPI-APs).
  8. gMG: Positive anti-acetylcholine receptor (AChR) antibody; MGFA clinical classification; MG-ADL total score; IVIG use, if applicable; immunosuppressive therapy history; and prior chronic plasmapheresis or plasma exchange, if applicable.
  9. NMOSD: Immunoassay confirming the presence of anti-aquaporin-4 (AQP4) antibody.
  10. Documentation Required

    Continuation Response Documentation

    For continuation requests, submit chart notes or medical record documentation supporting a positive clinical response to Ultomiris. For NMOSD reauthorization, document no unacceptable toxicity or disease progression, reduced number and/or severity of relapses from baseline, and prescribing by or consultation with a neurologist.

    • Continuation documentation must support ongoing benefit from the current regimen.
    • NMOSD reauthorization requires anti-AQP4-positive adult status and a positive clinical response demonstrated by reduced relapse number and/or severity.
    Denial Risk

    STEC-HUS Is Excluded

    Ultomiris is not indicated for Shiga toxin-producing E. coli–related hemolytic uremic syndrome (STEC-HUS). Do not submit or continue Ultomiris for STEC-HUS; requests for this condition do not meet the covered aHUS indication.

    • For aHUS, documentation must establish that the condition is not caused by Shiga toxin and that Shiga toxin is absent.
    Denial Risk

    Diagnosis-Specific Criteria Not Met

    Requests are at risk for denial when the applicable diagnosis-specific initial or continuation criteria are not satisfied or cannot be documented.

    • PNH: Confirm GPI-AP deficiency by flow cytometry with at least 5% PNH cells or at least 51% GPI-AP-deficient polymorphonuclear cells; subcutaneous dosing requires age 18 or older.
    • aHUS: Confirm ADAMTS13 activity above 5%, absence of Shiga toxin, and age 18 or older for subcutaneous dosing.
    • gMG: Member must be AChR-antibody positive, MGFA class II-IV, have an MG-ADL score of at least 6, and satisfy the required immunosuppressive therapy and/or chronic plasmapheresis, plasma exchange, or IVIG history.
    • NMOSD initial therapy: Member must be an AQP4-antibody-positive adult, have a qualifying core clinical characteristic and a relapse requiring rescue therapy within the prior 12 months, and receive treatment from or in consultation with a neurologist.
    • NMOSD continuation: Reauthorization requires no unacceptable toxicity or disease progression and a positive clinical response from baseline.
    Denial Risk

    Prohibited Concomitant Therapy

    Do not use Ultomiris concomitantly with restricted therapies. The combination is prohibited for both gMG and NMOSD requests.

    • gMG: Do not combine with another complement inhibitor, such as Soliris or Zilbrysq, or with a neonatal Fc receptor blocker, such as Vyvgart, Vyvgart Hytrulo, or Rystiggo.
    • NMOSD: Do not combine with another complement inhibitor such as eculizumab, anti-CD20 therapy such as rituximab, an anti-CD19 antibody such as inebilizumab-cdon, or an IL-6 receptor antagonist such as satralizumab-mwge.
    Denial Risk

    Not Medically Necessary

    Ultomiris is considered not medically necessary when the member does not meet the applicable coverage criteria, including diagnosis-specific initial criteria or required continuation criteria.

    • Do not request or continue coverage when required clinical documentation, eligibility, response, safety, or prescribing requirements are absent or unmet.
    For subcutaneous dosing, the member is 18 years of age or older.Age ≥18 for subcutaneous dosing

    aHUS — 6-Month Initial Authorization

    Authorization of 6 months may be granted when all criteria are met.

    6-month initial aHUS authorization

    • Diagnosis is atypical hemolytic uremic syndrome (aHUS) not caused by Shiga toxin.
    • ADAMTS13 activity level is above 5%.ADAMTS13 activity >5%
    • Shiga toxin is absent.
    • For subcutaneous dosing, the member is 18 years of age or older.Age ≥18 for subcutaneous dosing

    gMG — 6-Month Initial Authorization

    Authorization of 6 months may be granted when all criteria are met.

    6-month initial gMG authorization

    • Anti-acetylcholine receptor (AChR) antibody positive.
    • Myasthenia Gravis Foundation of America (MGFA) clinical classification II to IV.MGFA Class II–IV
    • MG-ADL total score is at least 6.MG-ADL ≥6
    • Prior treatment failure

      • Failed treatment over at least one year with at least two immunosuppressive therapies.≥2 therapies over ≥1 year

        Examples include azathioprine, cyclosporine, mycophenolate, tacrolimus, methotrexate, cyclophosphamide, and rituximab.

      • Failed at least one immunosuppressive therapy and required chronic plasmapheresis or plasma exchange (PE) or IVIG.≥1 therapy plus chronic plasmapheresis, PE, or IVIG
    • The requested medication will not be used in combination with another complement inhibitor or neonatal Fc receptor blocker.

    NMOSD — 6-Month Initial Authorization

    Authorization of 6 months may be granted for adult NMOSD when all criteria are met.

    6-month initial NMOSD authorization

    • Anti-aquaporin-4 (AQP4) antibody positive.
    • The medication is prescribed by, or in consultation with, a neurologist.
    • Qualifying NMOSD core clinical characteristic

      • Optic neuritis.
      • Acute myelitis.
      • Area postrema syndrome, including otherwise unexplained hiccups or nausea and vomiting.
      • Acute brainstem syndrome.
      • Symptomatic narcolepsy or acute diencephalic clinical syndrome with NMOSD-typical diencephalic MRI lesions.
      • Symptomatic cerebral syndrome with NMOSD-typical brain lesions.
    • The member experienced a relapse requiring rescue therapy within the 12 months before initiating therapy.Relapse requiring rescue therapy within prior 12 months
    • The requested drug will not be administered concomitantly with another complement inhibitor, anti-CD20 therapy, anti-CD19 antibody, or IL-6 receptor antagonist.
  11. The member demonstrates a positive response to therapy, such as normalization of LDH levels or platelet counts.
  12. gMG — 12-Month Continuation Authorization

    Authorization of 12 months may be granted for continued treatment when all criteria are met.

    12-month continuation gMG authorization

    • There is no evidence of unacceptable toxicity or disease progression while on the current regimen.
    • The member demonstrates a positive response to therapy, such as improvement in MG-ADL score or improvement from baseline in QMG total score.

    NMOSD — 12-Month Continuation Authorization

    Authorization of 12 months may be granted for continued adult NMOSD treatment when all criteria are met.

    12-month continuation NMOSD authorization

    • The adult member is anti-aquaporin-4 (AQP4) antibody positive.
    • There is no evidence of unacceptable toxicity or disease progression while on the current regimen.
    • The member demonstrates a positive clinical response from baseline, shown by a reduction in the number and/or severity of relapses.Reduction in number and/or severity of relapses from baseline
    • The medication is prescribed by, or in consultation with, a neurologist.